Heterodimeric antibodies that bind CD3 and CLDN6
Provided herein are novel CLDN6 binding domains, and anti-CLDN6×anti-CD3 antibodies that include such CLDN6 binding domains. Also provided herein are methods of using such antibodies for the treatment of CLDN6-associated cancers.
1. A composition comprising a bispecific antibody that binds human CD3 and human CLDN6 comprising:
a) a first monomer comprising the amino acid sequence set forth in SEQ ID NO: 567;
b) a second monomer comprising the amino acid sequence set forth in SEQ ID NO: 568; and
c) a third monomer comprising the amino acid sequence set forth in SEQ ID NO: 569.
2. A nucleic acid composition comprising:
a) a first nucleic acid encoding said first monomer of claim 1 ;
b) a second nucleic acid encoding said second monomer claim 1 ; and
c) a third nucleic acid encoding said third monomer of claim 1 .
3. An expression vector composition comprising:
a) a first expression vector comprising said first nucleic acid of claim 2 ;
b) a second expression vector comprising said second nucleic acid of claim 2 ; and
c) a third expression vector comprising said third nucleic acid of claim 2 .
4. A host cell comprising said expression vector composition of claim 3 .
5. A method of making a composition according to claim 1 comprising culturing said host cell of claim 4 under conditions wherein said composition of claim 1 is expressed, and recovering said composition.